A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

This trial is testing a new type of CAR T-cell therapy called JV-213 — a treatment where your own immune cells are collected, genetically engineered in a lab to recognize and attack B-cell lymphoma cells (specifically targeting a protein called CD79b), and then given back to you. This is a phase 1 study focused on safety and dosing. **You may be eligible if...** - You have a B-cell lymphoma (such as DLBCL, follicular lymphoma, mantle cell lymphoma, or others) that has relapsed or is not responding to treatment - You have tried at least 2 prior treatment regimens (or 1 for Burkitt lymphoma) - You have measurable disease - You have adequate organ function **You may NOT be eligible if...** - You have active CNS (brain) lymphoma - You have had a prior stem cell transplant recently - You have serious infections or autoimmune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.